Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa

The goal of this document was to provide Canadian laboratories with a framework for consistent reporting and monitoring of multidrug resistant organisms (MDRO) and extensively drug resistant organisms (XDRO) for common gram-negative pathogens. This is the final edition of the interim recommendations...

Full description

Saved in:
Bibliographic Details
Published in:Canada communicable disease report 2018-01, Vol.44 (1), p.29-34
Main Authors: German, G J, Gilmour, M, Tipples, G, Adam, H J, Almohri, H, Bullard, J, Dingle, T, Farrell, D, Girouard, G, Haldane, D, Hoang, L, Levett, P N, Melano, R, Minion, J, Needle, R, Patel, S N, Rennie, R, Reyes, R C, Longtin, J, Mulvey, M R
Format: Article
Language:English
Subjects:
Acinetobacter
Advisory Committee Statement
Antibiotic resistance
Antibiotics
Antimicrobial agents
Authoring
Automation
Clinical isolates
Clinical microbiology
Consultation
Drug resistance
Enterobacteriaceae
FDA approval
Health surveillance
Infections
Infectious diseases
Laboratories
Microbiology
Multidrug resistance
Multidrug resistant organisms
Organisms
Pseudomonas aeruginosa
Public health
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of this document was to provide Canadian laboratories with a framework for consistent reporting and monitoring of multidrug resistant organisms (MDRO) and extensively drug resistant organisms (XDRO) for common gram-negative pathogens. This is the final edition of the interim recommendations, which were modified after one year of broad consultative review. This edition represents a consensus of peer-reviewed information and was co-authored by the Canadian Public Health Laboratory Network and the Canadian Association of Clinical Microbiology and Infectious Diseases. There are two main recommendations. The first recommendation provides standardized definitions for MDRO and XDRO for gram-negative organisms in clinical specimens. These definitions were limited to antibiotics that are commonly tested clinically and, to reduce ambiguity, resistance (rather than non-susceptibility) was used to calculate drug resistance status. The second recommendation identifies the use of standardized laboratory reporting of organisms identified as MDRO or XDRO. Through the broad consultation, which included public health and infection prevention and control colleagues, these definitions are ready to be applied for policy development. Both authoring organizations intend to review these recommendations regularly as antibiotic resistance testing evolves in Canada.
ISSN:1188-4169
1481-8531
1481-8531
DOI:10.14745/ccdr.v44i01a07